Southlake, TX — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has extended its distribution channel through a new distribution agreement with MedPhy Technologies Pvt. Ltd., located in Mumbai, India.
MedPhy Technologies Pvt. Ltd. will serve as HeartSciences' most recent distributorship, fulfilling the role of both importer and distributor. Their network will provide HeartSciences with market representation across India once full product rollout has begun.
"We are extremely excited to partner with HeartSciences to bring MyoVista Wavelet ECG (wavECG) to medical professionals in India," said Manojkumar Patil, Director, MedPhy Technologies Pvt. Ltd. "The emerging field of AI ECG offers the meaningful prospect of low-cost screening to help solve the diagnostic gap where millions of Indian people with heart disease remain undiagnosed until some sort of cardiac event, such as a heart attack."
Mr. Patil continued, "Cardiovascular diseases are a major health concern in our country. As per a WHO report, India accounts for about one-fifth of the 17.9 million deaths caused by heart attacks globally. The key to managing any heart problem is early diagnosis, and introducing HeartSciences MyoVista in India provides physicians with new patient information related to a patient's heart health."
Investor contact
Mark Komonoski, Integrous Communications · 877-255-8483 · [email protected]